IPOIAM
Iambic Therapeutics IPO Preview: AI Drug Discovery Meets Clinical Risk
Iambic Therapeutics Inc. (NASDAQ: IAM) is expected to list on 2026-10-15, and the IPO has priced at $16.00 per share after offering 9,375,000 shares. The company did not disclose a price range in the materials provided. The bull case is a fast-growing collaboration platform with clinical-stage assets; the bear case is that it still has to prove AI can translate into durable drug wins.
Oct 9, 20265 MIN